NCT03942653 2025-12-31Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland CarcinomaBig Ten Cancer Research ConsortiumPhase 2 Recruiting20 enrolled